Showing results (441-450 of 450) with videos related to

Sort By:
Pageof 45
You have reached the last page of results.This site can display upto 450 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinomaC Lavarino, S Pilotti, M Oggionni, et al.
Cell|April 5, 1996
The FHIT gene 3p14.2 is abnormal in lung cancerG Sozzi, M L Veronese, M Negrini, et al.
Cancer Research|February 15, 1996
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinomaS C Righetti, G Della Torre, S Pilotti, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1997
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerabilityF Belli, F Arienti, J Sulé-Suso, et al.
Human Gene Therapy|December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cellsF Arienti, F Belli, F Napolitano, et al.
Oncogene|October 24, 2007
Breast cancer metastases are molecularly distinct from their primary tumorsM Vecchi, S Confalonieri, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2013
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaM Maio, R Danielli, V Chiarion-Sileni, et al.
Cancer Research|June 1, 1997
Association between cigarette smoking and FHIT gene alterations in lung cancerG Sozzi, L Sard, L De Gregorio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
International Journal of Cancer|February 6, 1999
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1M Marchand, N van Baren, P Weynants, et al.
Pageof 45